208 related articles for article (PubMed ID: 16523808)
1. Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment.
Burnet NG; Jena R; Jefferies SJ; Stenning SP; Kirkby NF
Clin Oncol (R Coll Radiol); 2006 Mar; 18(2):93-103. PubMed ID: 16523808
[TBL] [Abstract][Full Text] [Related]
2. A mathematical model of the treatment and survival of patients with high-grade brain tumours.
Kirkby NF; Jefferies SJ; Jena R; Burnet NG
J Theor Biol; 2007 Mar; 245(1):112-24. PubMed ID: 17084863
[TBL] [Abstract][Full Text] [Related]
3. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
[TBL] [Abstract][Full Text] [Related]
5. Treating Glioblastoma Multiforme (GBM) with super hyperfractionated radiation therapy: Implication of temporal dose fractionation optimization including cancer stem cell dynamics.
Yu VY; Nguyen D; O'Connor D; Ruan D; Kaprealian T; Chin R; Sheng K
PLoS One; 2021; 16(2):e0245676. PubMed ID: 33524046
[TBL] [Abstract][Full Text] [Related]
6. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
[TBL] [Abstract][Full Text] [Related]
7. Modelling normal tissue isoeffect distribution in conformal radiotherapy of glioblastoma provides an alternative dose escalation pattern through hypofractionation without reducing the total dose.
Mangel L; Skriba Z; Major T; Polgár C; Fodor J; Somogyi A; Németh G
Acta Oncol; 2002; 41(2):162-8. PubMed ID: 12102161
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.
Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
11. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
; Bentzen SM; Agrawal RK; Aird EG; Barrett JM; Barrett-Lee PJ; Bliss JM; Brown J; Dewar JA; Dobbs HJ; Haviland JS; Hoskin PJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Morgan DA; Owen JR; Simmons S; Sumo G; Sydenham MA; Venables K; Yarnold JR
Lancet Oncol; 2008 Apr; 9(4):331-41. PubMed ID: 18356109
[TBL] [Abstract][Full Text] [Related]
12. Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Jones B; Sanghera P
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):441-8. PubMed ID: 17324531
[TBL] [Abstract][Full Text] [Related]
13. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
15. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
16. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.
Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445
[TBL] [Abstract][Full Text] [Related]
17. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04.
Murray KJ; Scott C; Zachariah B; Michalski JM; Demas W; Vora NL; Whitton A; Movsas B
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):59-64. PubMed ID: 10924972
[TBL] [Abstract][Full Text] [Related]
18. Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma.
Zschaeck S; Wust P; Graf R; Misch M; Onken J; Ghadjar P; Badakhshi H; Florange J; Budach V; Kaul D
Radiat Oncol; 2018 Dec; 13(1):251. PubMed ID: 30567592
[TBL] [Abstract][Full Text] [Related]
19. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
20. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG
Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]